Commercial-Scale mRNA / LNP CDMOs

· updated as new inspection, certificate, and trial data enters the platform

mRNA / LNP manufacturers on CDMO Signal: 17 listed. 6 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Pfizer CentreOne (also makes its own products, Signal Score 90.1), BioNTech (Mfg Services) (also makes its own products, Signal Score 82.1) and Merck KGaA / MilliporeSigma (CDMO) (also makes its own products, Signal Score 81.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Corden Pharma (Signal Score 83.1) and ReciBioPharm (Signal Score 82.9). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-01. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.

17
CDMOs tracked
17
Fully scored
13
With FDA records
53
FDA inspections
166
EMA/MHRA GMP certs
2
Warning letters

mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.

Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 20 NAI (no action), 31 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (42), Germany (41), Denmark (29), Italy (21), UNITED KINGDOM (19).

Last updated 2026-10-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PC
Kalamazoo, MI · McPherson, KS
Fully evidenced
Also makes its own products
90.1 100.0 4 insp · 14 GMP 2025-12-16 · NAI — 366 programs
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
4
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
5
WK
Jena, DE · Amsterdam, NL · San Diego, CA
82.9 100.0 1 insp · 13 GMP 2023-12-07 · VAI — —
6
BNT
Mainz, DE · Marburg, DE
Fully evidenced
Also makes its own products
82.1 100.0 0 insp · 8 GMP None on file — 28 programs
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
9
EK
Birmingham, AL · Vancouver, BC
81.5 99.8 2 insp · 2 GMP 2025-09-11 · NAI — —
10
ND
Milford, MA
80.3 100.0 4 insp · 0 GMP 2026-08-12 · NAI — —
11
AE
Fargo, ND
Hiring · 35 open roles
80.3 100.0 1 insp · 0 GMP 2024-11-08 · NAI — —
12
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
13
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
14
MR
Norwood, MA
Fully evidenced
In-house manufacturer
77.9 100.0 4 insp · 4 GMP 2025-11-21 · NAI — 10 programs
15
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
16
CVC
Tubingen, DE
Fully evidenced
Also makes its own products
75.3 100.0 0 insp · 7 GMP None on file — 4 programs
17
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
How we score CDMOs →

What to evaluate in a mRNA / LNP CDMO

IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

mRNA / LNP CDMOs — Frequently Asked Questions

Who are the top mRNA / LNP CDMOs?
Among mRNA / LNP manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Pfizer CentreOne, BioNTech (Mfg Services), Merck KGaA / MilliporeSigma (CDMO). The table above is the full list. CDMOs cannot pay to change a score.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 13 mRNA / LNP CDMOs with FDA inspection records and 166 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Related modalities
Plasmid DNA CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector